tirzepatide trial results (Zepbound; Eli Lilly and Co) demonstrated 47% greater relative weight loss compared to semaglutide (Wegovy; Novo Nordisk) in the SURMOUNT-5 phase 3b open-label trial. Full will be presented at a surmount-osa trial tirzepatide results Effect

The most commonly reported side effects include: Nausea and vomiting Diarrhoea or constipation Stomach pain and bloating Dizziness Headache or fatigue Low blood sugar (more likely in people with type 2 diabetes, especially when Wegovy is taken with other diabetes medication) Acid reflux and heartburn Insulin resistance Symptoms tend to vary from person to person, and most should settle as your body gets used to the medication

Unlike stimulants or over-the-counter supplements, it works with the bodys natural hormones to regulate hunger and blood sugar

This is not about second-guessing your pharmacy

In cardiovascular outcome trials (CVOTs) such as Empagliflozin Cardiovascular Outcome Event Trial in Type 2 diabetes Mellitus Patients (EMPA-REG OUTCOME), CANagliflozin cardioVascular Assessment Study (CANVAS) and The Dapagliflozin Effect on Cardiovascular EventsThrombolysis in Myocardial Infarction 58 (DECLARE-TIMI 58) [6], they reduced the onset and progression of DKD, which was confirmed in the dedicated kidney trial The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), which showed a canagliflozin-induced risk reduction for ESKD in people with DKD by 32% [7]

This range optimizes the balance between mechanical tension (which preserves muscle) and metabolic stress (which supports fat loss)